{"id":22984,"date":"2023-07-09T12:31:23","date_gmt":"2023-07-09T19:31:23","guid":{"rendered":"https:\/\/ameripharmastg.wpengine.com\/?p=22984"},"modified":"2026-03-20T15:29:53","modified_gmt":"2026-03-20T22:29:53","slug":"gbs-vs-cidp-what-is-the-difference","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/","title":{"rendered":"SGB vs. PDIC: \u00bfcu\u00e1l es la diferencia?"},"content":{"rendered":"<p>El s\u00edndrome de Guillain-Barr\u00e9 (SGB) y la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (PDIC) son trastornos autoinmunes que causan debilidad en todo el cuerpo.<\/p>\n\n\n\n<div  id=\"call-to-action-1575aa22c981fcec7f498157714a98fb\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHabla con un especialista\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAcerca de la asistencia para copagos\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>Algunos m\u00e9dicos consideran que la PDIC es una forma cr\u00f3nica del SGB. Sin embargo, existen varias diferencias entre la PDIC y el SGB. Comprender los signos y las causas caracter\u00edsticos del SGB y la PDIC le ayudar\u00e1 a prepararse mejor para afrontar estas enfermedades.<\/p>\n\n\n\n<p>Aqu\u00ed encontrar\u00e1 todo lo que necesita saber sobre estas dos enfermedades autoinmunes.<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#What_is_Guillain-Barre_Syndrome\" >\u00bfQu\u00e9 es el s\u00edndrome de Guillain-Barr\u00e9?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#What_is_Chronic_Inflammatory_Demyelinating_Polyneuropathy\" >\u00bfQu\u00e9 es la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Prevalence_of_GBS_vs_CIDP\" >Prevalencia de SGB frente a PDIC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Causes_of_CIDP_and_GBS\" >Causas de CIDP y SGB<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Risk_Factors_for_GBS_vs_CIDP\" >Factores de riesgo para el SGB frente a la PDIC<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Symptoms_of_GBS_and_CIDP\" >S\u00edntomas del s\u00edndrome de Guillain-Barr\u00e9 y la poliposis cirrosis hep\u00e1tica cr\u00f3nica (PDIC)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#GBS\" >S\u00edndrome de Guillain-Barr\u00e9<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#CIDP\" >PDIC<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Onset_and_Progression_of_GBS_and_CIDP\" >Inicio y progresi\u00f3n del s\u00edndrome de Guillain-Barr\u00e9 y la polineuropat\u00eda desmielinizante idiop\u00e1tica cr\u00f3nica (PDIC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Diagnostic_Tests_for_GBS_vs_CIDP\" >Pruebas de diagn\u00f3stico para GBS versus CIDP<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Treatment_Options_for_GBS_vs_CIDP\" >Opciones de tratamiento para el SGB frente a la PDIC<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Treatments_for_GBS\" >Tratamientos para el s\u00edndrome de Guillain-Barr\u00e9<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Treatments_for_CIDP\" >Tratamientos para la PDIC<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#How_Can_IVIG_Help_Those_with_GBS_and_CIDP\" >\u00bfC\u00f3mo puede la IgIV ayudar a las personas con s\u00edndrome de Guillain-Barr\u00e9 y poliomielitis cirrosis?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#IVIG_Procedure_for_GBS_vs_CIDP\" >Procedimiento de IVIG para GBS versus CIDP<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Cost_of_IVIG_Treatment_for_GBS_vs_CIDP\" >Costo del tratamiento con IgIV para el s\u00edndrome de Guillain-Barr\u00e9 frente a la PDIC<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Outlook_and_Recovery_for_GBS_vs_CIDP\" >Perspectivas y recuperaci\u00f3n para el s\u00edndrome de Guillain-Barr\u00e9 frente a la poliposis desmielinizante inflamatoria cr\u00f3nica (PDIC)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#Manage_CIDP_and_GBS_with_AmeriPharma%C2%AE_Specialty_Pharmacy\" >Maneje CIDP y GBS con la Farmacia Especializada AmeriPharma\u00ae<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-what-is-guillain-barre-syndrome\"><span class=\"ez-toc-section\" id=\"What_is_Guillain-Barre_Syndrome\"><\/span>\u00bfQu\u00e9 es el s\u00edndrome de Guillain-Barr\u00e9?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-guillain-barre-syndrome\/\">S\u00edndrome de Guillain-Barr\u00e9<\/a> El s\u00edndrome de Guillain-Barr\u00e9 (SGB), o polirradiculoneuropat\u00eda desmielinizante inflamatoria aguda (PDIA), es un trastorno autoinmune poco com\u00fan. En este trastorno, el sistema inmunitario ataca los nervios del sistema nervioso perif\u00e9rico, causando entumecimiento, hormigueo e incluso par\u00e1lisis total.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-chronic-inflammatory-demyelinating-polyneuropathy\"><span class=\"ez-toc-section\" id=\"What_is_Chronic_Inflammatory_Demyelinating_Polyneuropathy\"><\/span>\u00bfQu\u00e9 es la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/what-is-cidp\/\">Polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica<\/a> La polineuropat\u00eda displ\u00e1sica cr\u00f3nica (PDIC) es otra enfermedad autoinmune poco com\u00fan en la que el cuerpo ataca las vainas de mielina que a\u00edslan las c\u00e9lulas nerviosas sanas. Este trastorno neurol\u00f3gico tambi\u00e9n afecta la movilidad y provoca una disminuci\u00f3n de los sentidos.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-prevalence-of-gbs-vs-cidp\"><span class=\"ez-toc-section\" id=\"Prevalence_of_GBS_vs_CIDP\"><\/span>Prevalencia de SGB frente a PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El s\u00edndrome de Guillain-Barr\u00e9 se presenta en <a href=\"https:\/\/www.researchgate.net\/publication\/23669394_The_Epidemiology_of_Guillain-Barre_Syndrome_Worldwide_A_Systematic_Literature_Review\">1,1-1,8 de cada 100.000 personas<\/a> Anualmente y es ligeramente m\u00e1s com\u00fan en varones. La tasa de incidencia tambi\u00e9n aumenta en mayores de 50 a\u00f1os.<\/p>\n\n\n\n<p>La CIDP, por otro lado, se presenta en <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2707109\/\">1,9-7,7 de cada 100.000 personas<\/a> Cada a\u00f1o y ocurre el doble de veces en hombres que en mujeres. Tambi\u00e9n es m\u00e1s com\u00fan entre personas con diabetes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-causes-of-cidp-and-gbs\"><span class=\"ez-toc-section\" id=\"Causes_of_CIDP_and_GBS\"><\/span>Causas de CIDP y SGB<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Aunque la CIDP y el SGB est\u00e1n relacionados, se desconoce la causa exacta de ambas enfermedades. Los cient\u00edficos creen que son trastornos autoinmunes en los que el sistema inmunitario trata los nervios sanos como pat\u00f3genos y los destruye.<\/p>\n\n\n\n<p>En la mayor\u00eda de los casos, el SGB se presenta tras una infecci\u00f3n bacteriana o viral. Tambi\u00e9n puede desarrollarse tras una lesi\u00f3n, cirug\u00eda o vacunaci\u00f3n. Por otro lado, no parece haber un desencadenante de la PDIC.<\/p>\n\n\n\n<p>Los cient\u00edficos han encontrado varias prote\u00ednas relacionadas con las prote\u00ednas que controlan nuestro sistema inmunitario en la sangre de pacientes con estos trastornos. Sin embargo, a\u00fan se desconoce si estas prote\u00ednas causan las enfermedades o son consecuencia de ellas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-risk-factors-for-gbs-vs-cidp\"><span class=\"ez-toc-section\" id=\"Risk_Factors_for_GBS_vs_CIDP\"><\/span>Factores de riesgo para el SGB frente a la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Los factores m\u00e1s comunes que aumentan el riesgo de padecer SGB incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Tener m\u00e1s de 50 a\u00f1os<\/li>\n\n\n\n<li>Diarrea e infecci\u00f3n con <em>Campylobacter jejuni<\/em> bacterias<\/li>\n\n\n\n<li>Otras infecciones virales y bacterianas, como las causadas por el virus de Epstein-Barr (VEB) y el citomegalovirus (CMV).<\/li>\n<\/ul>\n\n\n\n<p>La CIDP no presenta factores de riesgo distintivos. Sin embargo, algunos factores que pueden aumentar el riesgo de padecer esta enfermedad incluyen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>S\u00edndrome de Guillain-Barr\u00e9<\/li>\n\n\n\n<li>C\u00e1ncer<\/li>\n\n\n\n<li>Vacunaci\u00f3n<\/li>\n\n\n\n<li>Infecciones virales<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-symptoms-of-gbs-and-cidp\"><span class=\"ez-toc-section\" id=\"Symptoms_of_GBS_and_CIDP\"><\/span>S\u00edntomas del s\u00edndrome de Guillain-Barr\u00e9 y la poliposis cirrosis hep\u00e1tica cr\u00f3nica (PDIC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-gbs\"><span class=\"ez-toc-section\" id=\"GBS\"><\/span>S\u00edndrome de Guillain-Barr\u00e9<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-symptoms\/\">Signos y s\u00edntomas del s\u00edndrome de Guillain-Barr\u00e9<\/a> Aparecen dentro de las tres semanas posteriores a la infecci\u00f3n. Comienzan con entumecimiento o debilidad en brazos y piernas. A medida que la enfermedad progresa, tambi\u00e9n pueden presentarse los siguientes s\u00edntomas:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Dolor de espalda<\/li>\n\n\n\n<li>Sensaci\u00f3n de hormigueo<\/li>\n\n\n\n<li>Dificultad para respirar y tragar<\/li>\n\n\n\n<li>Problemas de equilibrio y coordinaci\u00f3n<\/li>\n\n\n\n<li>Reflejos tendinosos profundos disminuidos o ausentes<\/li>\n\n\n\n<li>Debilidad en los m\u00fasculos de la cara y los ojos.<\/li>\n<\/ul>\n\n\n\n<p>Los cambios nerviosos tambi\u00e9n pueden causar problemas de visi\u00f3n, digestivos y palpitaciones. Estos s\u00edntomas podr\u00edan empeorar a lo largo de 3 semanas y provocar par\u00e1lisis corporal total. Sin embargo, no empeorar\u00e1n despu\u00e9s de la cuarta semana.<\/p>\n\n\n\n<div  id=\"call-to-action-b4d37cb79627eb9b8fe9866d58c7feb6\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia financiera para GBS o CIDP\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Programar una consulta<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cidp\"><span class=\"ez-toc-section\" id=\"CIDP\"><\/span>PDIC<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>La PDIC tiene un inicio m\u00e1s gradual que el SGB, y sus s\u00edntomas son m\u00e1s progresivos. La mayor\u00eda de los pacientes presentan debilidad y entumecimiento en brazos y piernas. Muy pocos pacientes presentan problemas faciales u oculares.<\/p>\n\n\n\n<p>Otros comunes <a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-symptoms\/\">S\u00edntomas de la PDIC<\/a> incluir:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Fatiga<\/li>\n\n\n\n<li>Visi\u00f3n doble<\/li>\n\n\n\n<li>P\u00e9rdida de reflejos<\/li>\n\n\n\n<li>Problemas de equilibrio y coordinaci\u00f3n<\/li>\n\n\n\n<li>Torpeza y dificultad para tragar<\/li>\n\n\n\n<li>Entumecimiento u hormigueo en las manos y los pies.<\/li>\n\n\n\n<li>Debilitamiento gradual y p\u00e9rdida de sensibilidad en brazos y piernas.<\/li>\n<\/ul>\n\n\n\n<p>Los s\u00edntomas de la CIDP afectan ambos lados del cuerpo y progresan gradualmente durante varios d\u00edas o semanas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-onset-and-progression-of-gbs-and-cidp\"><span class=\"ez-toc-section\" id=\"Onset_and_Progression_of_GBS_and_CIDP\"><\/span>Inicio y progresi\u00f3n del s\u00edndrome de Guillain-Barr\u00e9 y la polineuropat\u00eda desmielinizante idiop\u00e1tica cr\u00f3nica (PDIC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El SGB se presenta de forma m\u00e1s aguda que la PDIC. El SGB suele aparecer en cuesti\u00f3n de d\u00edas o semanas y suele aparecer despu\u00e9s de otro evento, como una infecci\u00f3n, una cirug\u00eda o una vacunaci\u00f3n. Dado que el SGB solo tarda unas semanas en desarrollarse por completo, se considera una neuropat\u00eda autoinmune aguda.<\/p>\n\n\n\n<p>La CIDP puede aparecer a lo largo de varias semanas, meses o incluso a\u00f1os, y rara vez se asocia con una infecci\u00f3n u otro evento m\u00e9dico previo. Se considera una neuropat\u00eda autoinmune cr\u00f3nica, ya que puede tardar a\u00f1os en detectarse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-diagnostic-tests-for-gbs-vs-cidp\"><span class=\"ez-toc-section\" id=\"Diagnostic_Tests_for_GBS_vs_CIDP\"><\/span>Pruebas de diagn\u00f3stico para GBS versus CIDP<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La PDIC puede presentarse en el contexto de ciertos trastornos sangu\u00edneos. La prueba m\u00e1s \u00fatil para distinguir el SGB de la PDIC es la velocidad de conducci\u00f3n nerviosa (VCN).<\/p>\n\n\n\n<p>Las NCV mostrar\u00e1n signos de da\u00f1o en la vaina que rodea el nervio en la CIDP y ciertas formas de SGB, mientras que otras formas de CIDP muestran un bloqueo en la transmisi\u00f3n de impulsos por los nervios.<\/p>\n\n\n\n<p>Si bien una punci\u00f3n lumbar o una biopsia de nervio pueden brindar informaci\u00f3n \u00fatil, generalmente no son necesarias para diagnosticar CIDP y GBS.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-treatment-options-for-gbs-vs-cidp\"><span class=\"ez-toc-section\" id=\"Treatment_Options_for_GBS_vs_CIDP\"><\/span>Opciones de tratamiento para el SGB frente a la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter\"><img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP.jpg\" alt=\"A gloved hand holding a needle\" class=\"wp-image-23209\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP.jpg 1920w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-1024x683.jpg 1024w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-768x512.jpg 768w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-1536x1024.jpg 1536w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-370x247.jpg 370w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-960x640.jpg 960w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/IVIG-treatment-GBS-vs-CIDP-1280x853.jpg 1280w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/><\/figure>\n<\/div>\n\n\n<p>El tratamiento m\u00e1s eficaz para la PDIC y el SGB es la inmunoterapia. Sin embargo, no es la \u00fanica opci\u00f3n. A continuaci\u00f3n, se presentan los tratamientos m\u00e1s comunes para estas dos enfermedades autoinmunes.<\/p>\n\n\n\n<div  id=\"call-to-action-5d790271b22c5e094ff9b5a49fd98299\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tInformaci\u00f3n del tratamiento\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tObtener autorizaci\u00f3n previa\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-treatments-for-gbs\"><span class=\"ez-toc-section\" id=\"Treatments_for_GBS\"><\/span>Tratamientos para el s\u00edndrome de Guillain-Barr\u00e9<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El m\u00e1s com\u00fan <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-treatment-options\/\">Opciones de tratamiento para el s\u00edndrome de Guillain-Barr\u00e9<\/a> Incluyen el recambio plasm\u00e1tico (RP) y la inmunoglobulina intravenosa (IGIV). Ambos tratamientos tienen resultados y efectos secundarios similares, que son f\u00e1cilmente controlables.<\/p>\n\n\n\n<p>Los esteroides no son eficaces en el SGB. Un anticuerpo monoclonal llamado eculizumab (EC) ha sido \u00fatil en el tratamiento de casos m\u00e1s graves y se encuentra en fase de pruebas adicionales.<\/p>\n\n\n\n<p>Algunos pacientes en etapas avanzadas del s\u00edndrome de Guillain-Barr\u00e9 pueden necesitar muchos cuidados de apoyo, incluido apoyo ventilatorio, durante varios meses antes de la recuperaci\u00f3n completa.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-treatments-for-cidp\"><span class=\"ez-toc-section\" id=\"Treatments_for_CIDP\"><\/span>Tratamientos para la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/cidp-treatment\/\">Tratamientos de CIDP<\/a> Incluyen la PE, la IgIV y los esteroides. Son igualmente eficaces. Los cient\u00edficos a\u00fan no han determinado la dosis \u00f3ptima de estos agentes.<\/p>\n\n\n\n<p>Si bien los pacientes experimentan una mejora significativa con el tratamiento, estos beneficios solo duran unas pocas semanas. Por lo tanto, es necesario realizar tratamientos cada pocas semanas, a veces durante a\u00f1os.<\/p>\n\n\n\n<p>Para los pacientes que no mejoran con los tratamientos anteriores, <a href=\"https:\/\/ameripharmaspecialty.com\/es\/discontinued\/cyclophosphamide\/\" type=\"link\" id=\"https:\/\/ameripharmaspecialty.com\/discontinued\/cyclophosphamide\/\">ciclofosfamida<\/a> es \u00fatil. La fisioterapia suele ser \u00fatil para los pacientes con CIDP.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-can-ivig-help-those-with-gbs-and-cidp\"><span class=\"ez-toc-section\" id=\"How_Can_IVIG_Help_Those_with_GBS_and_CIDP\"><\/span>\u00bfC\u00f3mo puede la IgIV ayudar a las personas con s\u00edndrome de Guillain-Barr\u00e9 y poliomielitis cirrosis?<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Inmunoglobulina intravenosa (<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16040333\/\">IgIV<\/a>) es un tratamiento aprobado por la FDA que puede ayudarle a controlar ambas enfermedades. La soluci\u00f3n de IgIV contiene anticuerpos extra\u00eddos del plasma de donantes sanos.<\/p>\n\n\n\n<p>Aunque el mecanismo de acci\u00f3n exacto sigue siendo un misterio, los cient\u00edficos creen que la IgIV trata las enfermedades autoinmunes al crear un equilibrio. Aporta al cuerpo suficientes anticuerpos saludables para evitar que un sistema inmunitario debilitado se autoataque.<\/p>\n\n\n\n<p>Al regular su sistema inmunol\u00f3gico, la IgIV puede aliviar sus s\u00edntomas y ayudarlo a recuperarse. Varios <a href=\"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010369.pub2\/full\">estudios<\/a> Apoyar la eficacia de <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-cidp\/\">IgIV para la PDIC<\/a> y SGB, por lo que puede elegir este tratamiento con confianza.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ivig-procedure-for-gbs-vs-cidp\"><span class=\"ez-toc-section\" id=\"IVIG_Procedure_for_GBS_vs_CIDP\"><\/span>Procedimiento de IVIG para GBS versus CIDP<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\/ivig\/\">Terapia con IgIV<\/a> Es un procedimiento sencillo. Tanto si tiene SGB como PDIC, el proceso se detalla a continuaci\u00f3n:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Ir\u00e1s a un centro de infusi\u00f3n, una cl\u00ednica o un hospital, o una enfermera especializada ir\u00e1 a tu casa.<\/li>\n\n\n\n<li>La enfermera insertar\u00e1 una aguja intravenosa en su brazo por v\u00eda intravenosa o subcut\u00e1nea y comenzar\u00e1 la infusi\u00f3n.<\/li>\n\n\n\n<li>Despu\u00e9s de aproximadamente 3 a 5 horas, toda la soluci\u00f3n de IgIV ingresar\u00e1 a su cuerpo.<\/li>\n<\/ol>\n\n\n\n<p>Este procedimiento es pr\u00e1cticamente indoloro. Solo sentir\u00e1 molestias cuando la enfermera le inserte la aguja en el brazo. Tambi\u00e9n podr\u00eda experimentar efectos secundarios leves, como dolor de cabeza y fiebre, que desaparecer\u00e1n poco despu\u00e9s de la infusi\u00f3n.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cost-of-ivig-treatment-for-gbs-vs-cidp\"><span class=\"ez-toc-section\" id=\"Cost_of_IVIG_Treatment_for_GBS_vs_CIDP\"><\/span>Costo del tratamiento con IgIV para el s\u00edndrome de Guillain-Barr\u00e9 frente a la PDIC<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>El <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/cost-of-ivig-treatment\/\">costo de la IgIV<\/a> La terapia es similar tanto para la PDIC como para el SGB. Puede variar entre $100 y $350 por gramo, dependiendo de diversos factores, como:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Edad<\/li>\n\n\n\n<li>Peso<\/li>\n\n\n\n<li><a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\/ivig-brand-reviews\/\">Marca de IgIV<\/a><\/li>\n\n\n\n<li>M\u00e9todo de inyecci\u00f3n<\/li>\n\n\n\n<li>N\u00famero de infusiones<\/li>\n<\/ul>\n\n\n\n<p>El costo total puede superar los $5,000 por persona. Sin embargo, se puede financiar con diversas ayudas financieras. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/financial-assistance\/\">asistencia para copagos<\/a> programas. El seguro tambi\u00e9n cubrir\u00e1 una parte de los costos dependiendo de su condici\u00f3n.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-outlook-and-recovery-for-gbs-vs-cidp\"><span class=\"ez-toc-section\" id=\"Outlook_and_Recovery_for_GBS_vs_CIDP\"><\/span>Perspectivas y recuperaci\u00f3n para el s\u00edndrome de Guillain-Barr\u00e9 frente a la poliposis desmielinizante inflamatoria cr\u00f3nica (PDIC)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El <a href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/guillain-barre-syndrome-life-expectancy\/\">Perspectivas a largo plazo para el s\u00edndrome de Guillain-Barr\u00e9<\/a> El pron\u00f3stico es prometedor, con un 95% de pacientes que se recuperan en diversos grados. Los s\u00edntomas suelen empeorar durante cuatro semanas antes de estabilizarse.<\/p>\n\n\n\n<p>La mayor\u00eda de las personas se recuperan en un plazo de 6 a 12 meses tras iniciar el tratamiento. En otras, la recuperaci\u00f3n puede tardar hasta 3 a\u00f1os. Algunas personas seguir\u00e1n experimentando debilidad muscular, mientras que otras podr\u00edan sufrir una reca\u00edda.<\/p>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/cidp\/living-with-cidp\/\">Vivir con CIDP<\/a> Var\u00eda de una persona a otra. La mayor\u00eda de las personas con PDIC experimentan una mejor\u00eda inmediata de sus s\u00edntomas tras recibir tratamiento. Otras pueden experimentar s\u00edntomas ocasionalmente.<\/p>\n\n\n\n<p>Muchas de las personas con CIDP tendr\u00e1n <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3987657\/\">alg\u00fan grado de discapacidad f\u00edsica<\/a>Sin embargo, los pacientes con ambas enfermedades pueden evitar la discapacidad y la par\u00e1lisis con una detecci\u00f3n temprana y un tratamiento adecuado.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-\"><\/h5>\n\n\n\n<div  id=\"call-to-action-8f5f23171c6d870127d49bc70699b42b\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tHabla con un especialista \t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tAcerca de la asistencia para copagos\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Consulte con un especialista<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-manage-cidp-and-gbs-with-ameripharma-specialty-pharmacy\"><span class=\"ez-toc-section\" id=\"Manage_CIDP_and_GBS_with_AmeriPharma%C2%AE_Specialty_Pharmacy\"><\/span>Maneje CIDP y GBS con la Farmacia Especializada AmeriPharma\u00ae<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"853\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient.jpg\" alt=\"Nurse taking a patient\u2019s blood pressure\" class=\"wp-image-23210\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient.jpg 1280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-1024x682.jpg 1024w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-768x512.jpg 768w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-370x247.jpg 370w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/GBS-vs-CIDP-nurse-patient-960x640.jpg 960w\" sizes=\"auto, (max-width: 1280px) 100vw, 1280px\" \/><\/figure>\n<\/div>\n\n\n<p>Si bien el s\u00edndrome de Guillain-Barr\u00e9 y la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica son afecciones similares, presentan diferencias notables. Con\u00f3zcalas y aprenda a reconocer los s\u00edntomas del SGB frente a la PDIC para poder consultar a un m\u00e9dico a tiempo.<\/p>\n\n\n\n<p>Si ya le han diagnosticado alguna de estas afecciones, podemos ayudarle a controlarlas. En AmeriPharma\u00ae Specialty Pharmacy, ofrecemos servicios de infusi\u00f3n a domicilio y medicamentos dif\u00edciles de conseguir para personas que padecen afecciones debilitantes en m\u00e1s de 40 estados y territorios de EE. UU.<\/p>\n\n\n\n<p><a href=\"https:\/\/ameripharmaspecialty.com\/es\/get-started\/\">Empezar<\/a> Cont\u00e1ctenos ahora para aprovechar nuestra asistencia con copagos, asistencia las 24 horas, los 7 d\u00edas de la semana, los 365 d\u00edas del a\u00f1o y coordinaci\u00f3n de atenci\u00f3n de servicio completo.<\/p>","protected":false},"excerpt":{"rendered":"<p>El s\u00edndrome de Guillain-Barr\u00e9 (SGB) y la polineuropat\u00eda desmielinizante inflamatoria cr\u00f3nica (PDIC) son trastornos autoinmunes que causan debilidad en todo el cuerpo. Algunos m\u00e9dicos consideran que la PDIC es una forma cr\u00f3nica del SGB. Sin embargo, existen varias diferencias entre la PDIC y el SGB.<\/p>","protected":false},"author":25,"featured_media":23208,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[5,20],"tags":[31],"class_list":["post-22984","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cidp","category-guillain-barre-syndrome","tag-dr-mark-alfonso"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GBS vs CIDP: What\u2019s the Difference? | AmeriPharma\u2122 Specialty<\/title>\n<meta name=\"description\" content=\"What is the difference between GBS vs. CIDP? Learn about their symptoms, causes, treatments, and more in this guide from AmeriPharma\u2122 Specialty Pharmacy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GBS vs CIDP: What\u2019s the Difference? | AmeriPharma\u2122 Specialty\" \/>\n<meta property=\"og:description\" content=\"What is the difference between GBS vs. CIDP? Learn about their symptoms, causes, treatments, and more in this guide from AmeriPharma\u2122 Specialty Pharmacy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-09T19:31:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T22:29:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Mark Alfonso, PharmD, BCMTMS\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/\"},\"author\":{\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\"},\"headline\":\"GBS vs. CIDP: What is the Difference?\",\"datePublished\":\"2023-07-09T19:31:23+00:00\",\"dateModified\":\"2026-03-20T22:29:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/\"},\"wordCount\":1477,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/wheelchair-GBS-vs-CIDP.jpg\",\"keywords\":[\"Dr. Mark Alfonso\"],\"articleSection\":[\"CIDP\",\"Guillain-Barre Syndrome\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/\",\"name\":\"GBS vs CIDP: What\u2019s the Difference? | AmeriPharma\u2122 Specialty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/wheelchair-GBS-vs-CIDP.jpg\",\"datePublished\":\"2023-07-09T19:31:23+00:00\",\"dateModified\":\"2026-03-20T22:29:53+00:00\",\"description\":\"What is the difference between GBS vs. CIDP? Learn about their symptoms, causes, treatments, and more in this guide from AmeriPharma\u2122 Specialty Pharmacy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/wheelchair-GBS-vs-CIDP.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/wheelchair-GBS-vs-CIDP.jpg\",\"width\":1920,\"height\":1440,\"caption\":\"A woman standing next to a person in a wheelchair\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/guillain-barre-syndrome\\\/gbs-vs-cidp-what-is-the-difference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GBS vs. CIDP: What is the Difference?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/91fbbfa457730010998bc804c0467310\",\"name\":\"Dr. Mark Alfonso, PharmD, BCMTMS\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g\",\"caption\":\"Dr. Mark Alfonso, PharmD, BCMTMS\"},\"description\":\"Dr. Mark Alfonso, PharmD was born and raised in Pueblo, CO. He received his pharmacy degree from the University of Colorado School of Pharmacy at the Anschutz Medical Campus in 2010. He was board certified in medication therapy management in 2022. The most rewarding part of his job is helping to answer patient questions and concerns. His areas of expertise are community pharmacy and medication therapy management. In his free time, he enjoys reading and running.\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/mark-alfonso\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SGB vs. PDIC: \u00bfCu\u00e1l es la diferencia? | AmeriPharma\u2122 Especialidad","description":"\u00bfCu\u00e1l es la diferencia entre el SGB y la PDIC? Conozca sus s\u00edntomas, causas, tratamientos y m\u00e1s en esta gu\u00eda de la Farmacia Especializada AmeriPharma\u2122.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/","og_locale":"es_MX","og_type":"article","og_title":"GBS vs CIDP: What\u2019s the Difference? | AmeriPharma\u2122 Specialty","og_description":"What is the difference between GBS vs. CIDP? Learn about their symptoms, causes, treatments, and more in this guide from AmeriPharma\u2122 Specialty Pharmacy.","og_url":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2023-07-09T19:31:23+00:00","article_modified_time":"2026-03-20T22:29:53+00:00","og_image":[{"width":1920,"height":1440,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg","type":"image\/jpeg"}],"author":"Dr. Mark Alfonso, PharmD, BCMTMS","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Mark Alfonso, PharmD, BCMTMS","Est. reading time":"8 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/"},"author":{"name":"Dr. Mark Alfonso, PharmD, BCMTMS","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310"},"headline":"GBS vs. CIDP: What is the Difference?","datePublished":"2023-07-09T19:31:23+00:00","dateModified":"2026-03-20T22:29:53+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/"},"wordCount":1477,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg","keywords":["Dr. Mark Alfonso"],"articleSection":["CIDP","Guillain-Barre Syndrome"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/","url":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/","name":"SGB vs. PDIC: \u00bfCu\u00e1l es la diferencia? | AmeriPharma\u2122 Especialidad","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg","datePublished":"2023-07-09T19:31:23+00:00","dateModified":"2026-03-20T22:29:53+00:00","description":"\u00bfCu\u00e1l es la diferencia entre el SGB y la PDIC? Conozca sus s\u00edntomas, causas, tratamientos y m\u00e1s en esta gu\u00eda de la Farmacia Especializada AmeriPharma\u2122.","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg","width":1920,"height":1440,"caption":"A woman standing next to a person in a wheelchair"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/es\/guillain-barre-syndrome\/gbs-vs-cidp-what-is-the-difference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"GBS vs. CIDP: What is the Difference?"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/91fbbfa457730010998bc804c0467310","name":"Dr. Mark Alfonso, PharmD, BCMTMS","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/df364e910b779452dd2f50a2c506c7f028521d079f2eb79d89b22b93f4bd45d0?s=96&d=mm&r=g","caption":"Dr. Mark Alfonso, PharmD, BCMTMS"},"description":"El Dr. Mark Alfonso, doctor en farmacia, naci\u00f3 y creci\u00f3 en Pueblo, Colorado. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Colorado, en el Campus M\u00e9dico Anschutz, en 2010. Obtuvo su certificaci\u00f3n en gesti\u00f3n de terapias farmacol\u00f3gicas en 2022. Lo m\u00e1s gratificante de su trabajo es ayudar a responder las preguntas e inquietudes de los pacientes. Sus \u00e1reas de especializaci\u00f3n son la farmacia comunitaria y la gesti\u00f3n de terapias farmacol\u00f3gicas. En su tiempo libre, disfruta de la lectura y correr.","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",1920,1440,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-300x225.jpg",300,225,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-768x576.jpg",768,576,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1024x768.jpg",1024,768,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1536x1152.jpg",1536,1152,true],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",1920,1440,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",16,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",600,450,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-86x65.jpg",86,65,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-167x125.jpg",167,125,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-280x210.jpg",280,210,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-370x278.jpg",370,278,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-960x720.jpg",960,720,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1280x960.jpg",1280,960,true]},"uagb_author_info":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"uagb_comment_info":0,"uagb_excerpt":"Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are both autoimmune disorders that cause weakness throughout the body. Some doctors consider CIDP to be a chronic form of GBS. However, there are several differences between CIDP and GBS.","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",1920,1440,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",1920,1440,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",1920,1440,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-300x225.jpg",300,225,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1024x768.jpg",1024,768,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1536x1152.jpg",1536,1152,true],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",1920,1440,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",16,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP.jpg",600,450,false],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-86x65.jpg",86,65,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-167x125.jpg",167,125,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-280x210.jpg",280,210,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-370x278.jpg",370,278,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-960x720.jpg",960,720,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2023\/07\/wheelchair-GBS-vs-CIDP-1280x960.jpg",1280,960,true]},"rttpg_author":{"display_name":"Dr. Mark Alfonso, PharmD, BCMTMS","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/mark-alfonso\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/cidp\/\" rel=\"category tag\">CIDP<\/a> <a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/guillain-barre-syndrome\/\" rel=\"category tag\">Guillain-Barre Syndrome<\/a>","rttpg_excerpt":"Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) are both autoimmune disorders that cause weakness throughout the body. Some doctors consider CIDP to be a chronic form of GBS. However, there are several differences between CIDP and GBS.","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=22984"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/22984\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/23208"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=22984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=22984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=22984"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}